26.59
-0.13(-0.49%)
Currency In USD
| Previous Close | 26.72 |
| Open | 26.22 |
| Day High | 27.07 |
| Day Low | 25.66 |
| 52-Week High | 47.65 |
| 52-Week Low | 10.44 |
| Volume | 1.32M |
| Average Volume | 1.26M |
| Market Cap | 1.76B |
| PE | -9.14 |
| EPS | -2.91 |
| Moving Average 50 Days | 31.63 |
| Moving Average 200 Days | 28.67 |
| Change | -0.13 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $1,441.97 as of March 08, 2026 at a share price of $26.59. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 2 years ago, it would be worth $1,885.82 as of March 08, 2026 at a share price of $26.59.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 12, 2026 12:00 AM GMT
RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
GlobeNewswire Inc.
Dec 12, 2025 4:00 PM GMT
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors – RADNOR, Pa., Dec. 1